Ultragenyx Pharmaceutical Inc
(FRA:UP0)
€
46.2
-0.4 (-0.86%)
Market Cap: 4.31 Bil
Enterprise Value: 3.76 Bil
PE Ratio: 0
PB Ratio: 13.42
GF Score: 81/100 Ultragenyx Pharmaceutical Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2020 / 04:30PM GMT
Release Date Price:
€65
(+4.00%)
Hannah Lynne Latimer
Morgan Stanley, Research Division - Research Associate
Welcome to the Morgan Stanley Global Healthcare Conference. I'm Hannah Latimer, a member of the biotech team. Before we start, please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. (Operator Instructions)
For this session, we have Emil Kakkis, President and CEO of Ultragenyx. Welcome.
Emil D. Kakkis;Hannah Lynne Latimer
Ultragenyx Pharmaceutical Inc. - President, CEO & Director;Morgan Stanley, Research Division - Research Associate<
Thanks for having me today.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot